Chemo plus H. pylori treatment for advanced stomach cancer
Part of Cancer, Digestive system, Infections clinical trials.
This trial tests whether adding H. pylori bacteria treatment to standard chemotherapy (before and after surgery) can improve outcomes for people with locally advanced stomach cancer. It combines oxaliplatin and S-1 chemo with antibiotics to clear the infection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a current H. pylori infection (stomach bacteria).
- Your gastric cancer is locally advanced (stage cT3/4a Nx or T2 N2/3, M0) and has not spread to other organs.
- You are between 18 and 75 years old and in generally good health (ECOG 0-1).
- Your blood tests and organ function are within safe limits for surgery and chemotherapy.
- You are willing to use contraception during and for 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether adding an immunotherapy drug (sintilimab) to standard chemotherapy (S-1 and oxaliplatin) can better treat locally advanced cancer at the junction of the esophagus and stomach. It may help shrink the tumor and control the cancer before or around surgery.
This phase 3 study compares two versions of a first-time treatment for HER2-negative advanced stomach or gastroesophageal cancer, both including immunotherapy (sintilimab). It looks for a safer or more effective way to slow cancer growth or improve outcomes.
This trial tests a new approach for locally advanced stomach cancer. It uses a heated chemotherapy bath (HIPEC) before giving a combination of two chemotherapy drugs (SOX or XELOX) plus an immunotherapy drug called serplulimab. This aims to shrink the tumor and improve the chances of successful surgery and long-term control.
This trial combines heated chemotherapy directly into the abdomen (HIPEC) with standard chemotherapy and an immunotherapy drug to treat advanced stomach cancer that has spread to the lining of the abdomen. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests whether adding two newer drugs (pucotenlimab and lenvatinib) to standard chemotherapy (SOX) works better than chemotherapy alone for people with advanced stomach or gastroesophageal junction cancer that is HER2-negative. The goal is to see if the combination slows cancer growth.
This trial tests whether adding the immunotherapy drug HLX10 (serplulimab) to standard chemotherapy (S-1 plus oxaliplatin) before and after surgery can improve outcomes for patients with advanced gastric or gastroesophageal junction cancer that has a high level of PD-L1 protein.
Hear when a new Chemotherapy Effect trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.